Extrawell Pharma.
Description Extrawell Pharmaceutical Holdings Limited, an investment holding company, engages in the development, manufacture, and sale of pharmaceutical products in the Peoples Republic of China. Its product portfolio comprises P-transfer factor oral solution for the treatment of diseases due to the weak cellular immune system; WISK for the prevention of wound deterioration, regeneration of new tissues, and recovery of hair follicles; Ozagrel Sodium Injection used to prevent the coagulation of platelets and facilitate relaxation of blood vessels; and Feining Pian, which is used for chronic cough, acute upper respiratory tract infection, infection associate with bronchitis, and emphysema. The company also involves in the marketing and distribution of imported pharmaceutical products, including GM-1 to re-establish functional recovery of central nervous system structures that have suffered damage of various origins; Indapamide for the treatment of high blood pressure; and Skin-Cap Spray for the relief of itching, redness, flaking, and scaling associated with psoriasis, dandruff, seborrheic dermatitis, seborrhea, and other squamous dermatosis. In addition, it engages in the commercial exploitation and development of genome-related technology; development and commercialization of oral insulin products; and provision of agency services. Further, the company holds gene invention rights. Extrawell Pharmaceutical Holdings Limited is headquartered in Wanchai, Hong Kong. To view the detailed information, you need to SUBSCRIBE with us. |
 |